Mainz Biomed B.V. (MYNZ)
NASDAQ: MYNZ · IEX Real-Time Price · USD
0.349
-0.031 (-8.16%)
At close: Jul 19, 2024, 4:00 PM
0.359
+0.010 (2.75%)
Pre-market: Jul 22, 2024, 7:33 AM EDT
Mainz Biomed B.V. Revenue
In the year 2023, Mainz Biomed B.V. had annual revenue of $895.48K with 69.00% growth. Revenue in the quarter ending December 31, 2023 was $214.76K with 11.11% year-over-year growth.
Revenue (ttm)
$895.48K
Revenue Growth
+69.00%
P/S Ratio
8.53
Revenue / Employee
$12,612
Employees
71
Market Cap
7.64M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
Dec 31, 2019 | 281.39K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
XWELL | 31.77M |
Precipio | 15.81M |
Vivos Therapeutics | 13.36M |
iCoreConnect | 9.03M |
NeuroMetrix | 5.27M |
Kineta | 5.16M |
Innovative Eyewear | 1.39M |
MYNZ News
- 13 days ago - Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test - GlobeNewsWire
- 19 days ago - Mainz Biomed Provides Half Year 2024 Corporate Update - GlobeNewsWire
- 6 weeks ago - Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 - GlobeNewsWire
- 7 weeks ago - Mainz Biomed Reports Results of 2024 Annual General Meeting - GlobeNewsWire
- 7 weeks ago - Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial - GlobeNewsWire
- 2 months ago - Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. - GlobeNewsWire
- 3 months ago - Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic - GlobeNewsWire